kabutan

KAKEN PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 96%, Oct-Dec Ordinary Profit Decreases by 91%

Fri Feb 6, 2026 3:30 pm JST Earnings

4521 KAKEN PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KAKEN PHARMACEUTICAL CO.,LTD. <4521> [TSE Prime] announced its financial results after the market closed on February 6th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) significantly dropped 95.5% from the same period last year to 1.17 billion yen. Progress toward the full-year plan of 2.80 billion yen was 41.9%, also falling below the five-year average of 106.1%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the January to March period (4Q) is expected to turn into a profit of 1.62 billion yen (compared to a loss of 4.80 billion yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit significantly dropped to 0.56 billion yen, a 91.0% decrease compared to the same period last year. The operating profit margin sharply declined from 23.7% in the same period last year to 1.9%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 54,685 8,873 9,304 6,675 177.1 93.5 Feb 6, 2024 J-GAAP
Apr - Dec, 2024 75,990 25,420 26,081 19,175 506.3 122.6 Feb 6, 2025 J-GAAP
Apr - Dec, 2025 57,617 554 1,172 1,398 36.9 41.9 Feb 6, 2026 J-GAAP
YoY -24.2% -97.8% -95.5% -92.7% -92.7%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 42,663 1,455 1,456 -341 -8.9 75 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 46,944 1,897 2,193 1,308 34.5 95 Nov 10, 2025 J-GAAP
YoY +10.0% +30.4% +50.6% － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 72,044 9,513 9,951 8,025 212.7 150 May 14, 2024 J-GAAP
Mar, 2025 94,035 21,034 21,279 13,945 365.4 190 May 12, 2025 J-GAAP
Mar, 2026 Guidance 86,300 2,100 2,800 2,300 60.7 190 Sep 26, 2025 J-GAAP
YoY -8.2% -90.0% -86.8% -83.5% -83.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 24,618 5,841 6,258 4,889 129.1 23.7 Feb 6, 2025 J-GAAP
Jan - Mar, 2025 18,045 -4,386 -4,802 -5,230 -137.1 -24.3 May 12, 2025 J-GAAP
Apr - Jun, 2025 18,867 14 417 271 7.1 0.1 Aug 7, 2025 J-GAAP
Jul - Sep, 2025 20,489 189 190 721 19.0 0.9 Nov 10, 2025 J-GAAP
Oct - Dec, 2025 18,261 351 565 406 10.7 1.9 Feb 6, 2026 J-GAAP
YoY -25.8% -94.0% -91.0% -91.7% -91.7%

Related Articles